Combined innate and adaptive immunotherapy overcomes resistance of immunologically cold syngeneic murine neuroblastoma to checkpoint inhibition

Pediatric Cancer Immunotherapy: Opportunities and Challenges

(2018) Mary Frances Wedekind et al.   PEDIATRIC DRUGS

Tumor-Specific Inhibition of In Situ Vaccination by Distant Untreated Tumor Sites

(2018) Zachary S. Morris et al.   Cancer Immunology Research

Immuno-Oncology: Emerging Targets and Combination Therapies

(2018) Henry T. Marshall et al.   Frontiers in Oncology

Advances in Anti-GD2 Immunotherapy for Treatment of High-risk Neuroblastoma

(2018) Julie Voeller et al.   JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY

High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors

(2018) Saman Maleki Vareki   Journal for ImmunoTherapy of Cancer

Effective Combination of Innate and Adaptive Immunotherapeutic Approaches in a Mouse Melanoma Model

(2017) Alexander L. Rakhmilevich et al.   JOURNAL OF IMMUNOLOGY

Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers

(2017) Aaron M. Goodman et al.   MOLECULAR CANCER THERAPEUTICS

Gut microbiota modulation of chemotherapy efficacy and toxicity

(2017) James L. Alexander et al.   Nature Reviews Gastroenterology & Hepatology

Treatment and survival of childhood neuroblastoma: Evidence from a population-based study in the United States

(2017) Diarmuid Coughlan et al.   PEDIATRIC HEMATOLOGY AND ONCOLOGY

DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity

(2017) Claire Vanpouille-Box et al.   Nature Communications

In SituTumor Vaccination by Combining Local Radiation and Tumor-Specific Antibody or Immunocytokine Treatments

(2016) Zachary S. Morris et al.   CANCER RESEARCH

Fine-Tuning Cancer Immunotherapy: Optimizing the Gut Microbiome

(2016) J. M. Pitt et al.   CANCER RESEARCH

Anti-GD2 mAbs and next-generation mAb-based agents for cancer therapy

(2016) Zulmarie Perez Horta et al.   Immunotherapy

Neuroblastoma

(2016) Katherine K. Matthay et al.   Nature Reviews Disease Primers

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

(2015) Christina Twyman-Saint Victor et al.   NATURE

Releasing the Brakes on Cancer Immunotherapy

(2015) Antoni Ribas   NEW ENGLAND JOURNAL OF MEDICINE

Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy

(2015) A. Sivan et al.   SCIENCE

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

(2015) E. M. Van Allen et al.   SCIENCE

Neoantigens in cancer immunotherapy

(2015) T. N. Schumacher et al.   SCIENCE

Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota

(2015) M. Vetizou et al.   SCIENCE

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

(2015) N. A. Rizvi et al.   SCIENCE

Anti-GD2 strategy in the treatment of neuroblastoma

(2014) R.K. Yang et al.   DRUGS OF THE FUTURE

Phase I Trial of a Novel Anti-GD2 Monoclonal Antibody, Hu14.18K322A, Designed to Decrease Toxicity in Children With Refractory or Recurrent Neuroblastoma

(2014) Fariba Navid et al.   JOURNAL OF CLINICAL ONCOLOGY

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

(2014) Matthew M. Gubin et al.   NATURE

Intratumoral treatment of smaller mouse neuroblastoma tumors with a recombinant protein consisting of IL-2 linked to the Hu14.18 antibody increases intratumoral CD8+ T and NK cells and improves survival

(2013) Richard K. Yang et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

A transplantable TH-MYCN transgenic tumor model in C57Bl/6 mice for preclinical immunological studies in neuroblastoma

(2013) Michiel Kroesen et al.   INTERNATIONAL JOURNAL OF CANCER

Mutational heterogeneity in cancer and the search for new cancer-associated genes

(2013) Michael S. Lawrence et al.   NATURE

Signatures of mutational processes in human cancer

(2013) Ludmil B. Alexandrov et al.   NATURE

Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples

(2013) Kristian Cibulskis et al.   NATURE BIOTECHNOLOGY

Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells

(2013) M. J. Selby et al.   Cancer Immunology Research

Immunosuppressive Microenvironment in Neuroblastoma

(2013) Vito Pistoia et al.   Frontiers in Oncology

TEM8/ANTXR1 Blockade Inhibits Pathological Angiogenesis and Potentiates Tumoricidal Responses against Multiple Cancer Types

(2012) Amit Chaudhary et al.   CANCER CELL

Selective blockade of tumor angiogenesis

(2012) Amit Chaudhary et al.   CELL CYCLE

Intratumoral Delivery of Low Doses of Anti-CD40 mAb Combined With Monophosphoryl Lipid A Induces Local and Systemic Antitumor Effects in Immunocompetent and T Cell-Deficient Mice

(2012) Tyler J. Van De Voort et al.   JOURNAL OF IMMUNOTHERAPY

Broad Expression Analysis of Human ANTXR1/TEM8 Transcripts Reveals Differential Expression and Novel Splizce Variants

(2012) Micaela Vargas et al.   PLoS One

The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data

(2010) A. McKenna et al.   GENOME RESEARCH

Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma

(2010) Alice L. Yu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti-CTLA-4 Antibody

(2009) M. Z. Dewan et al.   CLINICAL CANCER RESEARCH